Revolution Medicines has raised $232 million through multiple equity financing rounds to support its development of novel small molecule inhibitors of frontier oncology targets within notorious cancer pathways.
We are supported by a leading syndicate of investors, which include our founding investor, Third Rock Ventures, and BVF, Casdin Capital, Cormorant, Deerfield, Fidelity, Nextech, Tavistock, The Column Group and Vivo Ventures.
Furthermore, our lead clinical candidate, RMC-4630, is the focus of an exclusive global research, development and commercialization agreement with Sanofi, under which we received a $50 million upfront payment, and Sanofi agreed to cover substantially all research and all development costs for the joint SHP2 program. Sanofi received an exclusive worldwide license for global commercialization of any approved products targeting SHP2, subject to a U.S. co-promote right for Revolution Medicines. Revolution Medicines and Sanofi have agreed to enter into a 50/50 profit and loss share arrangement in the U.S., and, subject to certain limitations, we are entitled to receive a tiered royalty ranging from high single digit to mid-teen percentages on sales in other markets. We could also receive more than $500 million in development and regulatory milestone payments.